Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39930 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL515689 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL912891 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL23722964 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL561138 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL23515345 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL1578111 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL2723355 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL22777473 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL17932953 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736944-A2 | POLYPEPTIDES AND USES THEREOF | MedImmune Limited (GB) | 2026-05-06 | — | — | EP | claimed |
| EP-4598585-A1 | PRODUCT | Oxford University Innovation Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | claimed |
| WO-2024074837-A1 | Product | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| EP-4240750-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | claimed |
| WO-2022096394-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | claimed |
| EP-2547355-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-01-11 | — | — | EP | claimed |
| US-20150265733-A1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | Universität Bern (CH) | 2015-09-24 | — | — | US | claimed |
| EP-2470672-A1 | COMPOUND | The Queen's University of Belfast (GB) | 2012-07-04 | — | — | EP | claimed |
| US-20120156691-A1 | COMPOUND | QUEEN'S UNIVERSITY OF BELFAST | 2012-06-21 | — | — | US | claimed |
| WO-2011024006-A1 | COMPOUND | QUEEN'S UNIVERSITY OF BELFAST (GB) | 2011-03-03 | — | — | WO | claimed |
| EP-4744668-A2 | POLYNUCLEOTIDE CONSTRUCTS | Sirius Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630600-B2 | GLP-1 and glucagon dual agonist peptides with improved biological stability | MEDIMMUNE LIMITED (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-4078651-B1 | FOURIER TRANSFORM QUADRUPOLE CALIBRATION METHOD | DH TECHNOLOGIES DEV PTE LTD (SG) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736944-A2 | POLYPEPTIDES AND USES THEREOF | MedImmune Limited (GB) | 2026-05-06 | — | — | EP | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1846447-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082205-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630600-B2 | GLP-1 and glucagon dual agonist peptides with improved biological stability | GLP1R, GIPR, GCGR | LMNA 1573/4885BLM 3738/4885TSHR 142/4885 |
| US-20150265733-A1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | BRS3, VIP, GRPR | LMNA 918/4885BLM 770/4885TSHR 182/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | LMNA 3249/4885BLM 4012/4885TSHR 3413/4885 |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | LMNA 318/4885BLM 3687/4885TSHR 2063/4885 |
| US-20120156691-A1 | COMPOUND | DNPEP, TMPRSS15, PEPD | LMNA 2269/4885BLM 3222/4885TSHR 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.